Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020.
作者信息
Dong Caixia, Ding Yuwei, Weng Shanshan, Li Guichao, Huang Yanqing, Hu Hanguang, Zhang Zhen, Zhang Suzhan, Yuan Ying
机构信息
Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Cancer Center, Zhejiang University, Hangzhou 310058, China.
出版信息
Chin J Cancer Res. 2021 Jun 30;33(3):302-307. doi: 10.21147/j.issn.1000-9604.2021.03.02.
Abstract
摘要
相似文献
1
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020.
Chin J Cancer Res. 2021 Jun 30;33(3):302-307. doi: 10.21147/j.issn.1000-9604.2021.03.02.
2
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018.
Chin J Cancer Res. 2019 Jun;31(3):423-425. doi: 10.21147/j.issn.1000-9604.2019.03.03.
3
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019.
Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11.
4
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version).
Chin J Cancer Res. 2019 Feb;31(1):117-134. doi: 10.21147/j.issn.1000-9604.2019.01.07.
5
CSCO guidelines for colorectal cancer version 2022: Updates and discussions.
Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01.
6
CSCO guidelines for colorectal cancer version 2023: Updates and insights.
Chin J Cancer Res. 2023 Jun 30;35(3):233-238. doi: 10.21147/j.issn.1000-9604.2023.03.02.
7
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
8
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version).
Chin J Cancer Res. 2019 Feb;31(1):84-98. doi: 10.21147/j.issn.1000-9604.2019.01.05.
9
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version).
Chin J Cancer Res. 2019 Feb;31(1):99-116. doi: 10.21147/j.issn.1000-9604.2019.01.06.
10
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version).
Chin J Cancer Res. 2021 Jun 30;33(3):289-301. doi: 10.21147/j.issn.1000-9604.2021.03.01.
引用本文的文献
1
Multimodal Preoperative Management of Rectal Cancer: A Review of the Existing Guidelines.
Medicina (Kaunas). 2025 Jun 24;61(7):1132. doi: 10.3390/medicina61071132.
2
Updates of CSCO guidelines for colorectal cancer version 2025.
Chin J Cancer Res. 2025 Jun 30;37(3):297-302. doi: 10.21147/j.issn.1000-9604.2025.03.01.
3
Efficacy observation of sequential TAS-102 following regorafenib as a later-line treatment in patients with metastatic colorectal cancer: a cohort study.
J Gastrointest Oncol. 2025 Apr 30;16(2):354-366. doi: 10.21037/jgo-2025-47. Epub 2025 Apr 27.
4
Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review.
Immunotherapy. 2024;16(10):649-657. doi: 10.1080/1750743X.2024.2350355. Epub 2024 May 17.
5
The development and implementation of pathological parameters and molecular testing impact prognosis of colorectal adenocarcinoma.
J Natl Cancer Cent. 2024 Feb 7;4(1):74-85. doi: 10.1016/j.jncc.2024.02.001. eCollection 2024 Mar.
6
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
7
Irinotecan plus raltitrexed as second‑line chemotherapy for metastatic colorectal cancer: A retrospective study.
Oncol Lett. 2024 Jun 28;28(3):409. doi: 10.3892/ol.2024.14542. eCollection 2024 Sep.
8
Comparative characteristics of early-onset vs. late-onset advanced colorectal cancer: a nationwide study in China.
BMC Cancer. 2024 Apr 20;24(1):503. doi: 10.1186/s12885-024-12278-7.
9
Machine learning-based identification of colorectal advanced adenoma using clinical and laboratory data: a phase I exploratory study in accordance with updated World Endoscopy Organization guidelines for noninvasive colorectal cancer screening tests.
Front Oncol. 2024 Feb 23;14:1325514. doi: 10.3389/fonc.2024.1325514. eCollection 2024.
10
Circulation immune cell landscape in canonical pathogenesis of colorectal adenocarcinoma by CyTOF analysis.
iScience. 2024 Feb 15;27(3):109229. doi: 10.1016/j.isci.2024.109229. eCollection 2024 Mar 15.
本文引用的文献
1
[China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing)].
Zhonghua Zhong Liu Za Zhi. 2021 Jan 23;43(1):16-38. doi: 10.3760/cma.j.cn112152-20210105-00010.
2
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
Oncologist. 2021 Jan;26(1):e90-e98. doi: 10.1634/theoncologist.2020-0563. Epub 2020 Sep 3.
3
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7.
4
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
5
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by Status in Patients With Locally Advanced Rectal Cancer.
J Clin Oncol. 2020 Dec 20;38(36):4231-4239. doi: 10.1200/JCO.20.01932. Epub 2020 Oct 29.
6
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019.
Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11.
7
Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.
JAMA Netw Open. 2020 Jul 1;3(7):e2011036. doi: 10.1001/jamanetworkopen.2020.11036.
8
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Oncologist. 2020 Dec;25(12):e1855-e1863. doi: 10.1634/theoncologist.2020-0643. Epub 2020 Aug 3.
9
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Lancet Oncol. 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27.
10
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14.
Zotero 插件